<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00986635</url>
  </required_header>
  <id_info>
    <org_study_id>RIV139/09</org_study_id>
    <nct_id>NCT00986635</nct_id>
  </id_info>
  <brief_title>Effect of Rivaroxaban on Coagulation Parameters- an ex Vivo Study</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johann Wolfgang Goethe University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johann Wolfgang Goethe University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rivaroxaban represent a new class of anticoagulation agents. As an oral direct factor Xa
      inhibitor it has been effective in preventing venous thromboembolism in patients undergoing
      elective orthopaedic surgery. This ex vivo study is undertaken to investigate the ex-vivo
      effects of Xarelto® on different coagulation parameters.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To validate the effects of Rivaroxaban on coagulation parameters plasma samples of patients
      after hip or knee replacement surgery treated with Rivaroxaban 10 mg/d are investigated.

      Plasma samples are obtained by blood collection before, after 2 hours and after 12 hours
      after Rivaroxaban dosing in steady state (on 3rd - 5th day).

      Several techniques, including clot-based tests, chromogenic assays and ELISA´s are used for
      coagulation assays in our coagulation laboratory Frankfurt/Main. The influence of Rivaroxaban
      on different coagulation assays should be investigated in our coagulation laboratory.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">April 2011</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Differences in Laboratory Coagulation Parameters</condition>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Plasma samples
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        patients after hip or knee replacement surgery
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients after hip or knee replacement surgery treated with Rivaroxaban 10 mg/d

          -  must be able to accept blood sampling
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Helen Mani, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johann Wolfgang Goethe University Hospital Frankfurt/Main Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Frankfurt</name>
      <address>
        <city>Frankfurt am Main</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 29, 2009</study_first_submitted>
  <study_first_submitted_qc>September 29, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 30, 2009</study_first_posted>
  <last_update_submitted>April 7, 2011</last_update_submitted>
  <last_update_submitted_qc>April 7, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 8, 2011</last_update_posted>
  <responsible_party>
    <name_title>Prof. Dr. Edelgard Lindhoff-Last, MD</name_title>
    <organization>Vascular Medicine, Johann Wolfgang Goethe University Hospital Frankfurt/Main</organization>
  </responsible_party>
  <keyword>Activated partial thromboplastin time</keyword>
  <keyword>Thrombin clotting Time</keyword>
  <keyword>Anti-Xa-activity</keyword>
  <keyword>Factor X-activity</keyword>
  <keyword>Factor XIII-activity</keyword>
  <keyword>Antithrombin (based on factor II)</keyword>
  <keyword>Antithrombin (based on factor X&lt;9</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antithrombins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

